HealthifyMe
PrivateLast Round
Series D
Oct 25, 2024
Est. Valuation
$550M
Total Funding Raised
$175.25M
Company Overview
HealthifyMe operates in Healthcare & Life Sciences and is based in Bangalore. Its latest recorded funding round was a Series D round in October 2024.
HealthifyMe is a health and wellness technology company that offers an AI-powered online fitness application to help individuals achieve their fitness goals and enhance corporate wellness through personalized coaching and automated analytics.
Sector
Healthcare & Life Sciences
Verticals
Sports & Fitness, NLP & Conversational AI, Health IoT, Subscription Commerce
Business Model
B2C
Customer Profile
Subscription SaaS, Freemium, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HealthifyMe Comparables
Compare HealthifyMe with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MyFitnessPal | 83% | |
| Fitelo | 81% | |
| GOQii | 81% |
For institutional investors. Book with your work email.
HealthifyMe Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Oct 25, 2024 | ||||
| Growth Equity | Jun 7, 2023 | ||||
| Series C | Jul 20, 2021 | ||||
| Series B Extension | Nov 16, 2018 | ||||
| Series B | Feb 9, 2018 | ||||
Series A Extension | Dec 28, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HealthifyMe Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Van Lanschot Kempen | Series D, Growth Equity |
| Khosla Ventures | Series C, Series D, Growth Equity |
| DI Investment Holding Limited | Series B |
| Atlas Asset Management | Series B |
| Blume Ventures | Series B Extension, Series D, Growth Equity, Series B, Series A |
| Inventus Capital Partners | Series C, Series B Extension, Series A, Series B |
| Samsung NEXT Ventures | Series B Extension, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Partnership with Harvey Speciality clinics in Coimbatore, Tamil Nadu.
- Mar 4, 2026
Introduced Healthify Rx Program for GLP medication consultations.
For institutional investors. Book with your work email.
HealthifyMe Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HealthifyMe's valuation, stock price, and market status.
Is HealthifyMe a public or private company?
HealthifyMe is a private company.
What is the current stock price of HealthifyMe?
HealthifyMe is a private company, so its shares have no public market price. Caplight tracks HealthifyMe's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HealthifyMe worth (valuation)?
HealthifyMe's valuation is estimated at $550.0M based on funding round data.
Can I buy HealthifyMe stock?
HealthifyMe shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HealthifyMe's last funding round?
HealthifyMe's most recent funding round was Series D on October 25, 2024.
Who are the main investors in HealthifyMe?
Key investors in HealthifyMe include Khosla Ventures, Blume Ventures, InnoVen Capital, Chiratae Ventures, Leapfrog Investments.
Will HealthifyMe IPO soon?
No public IPO plans have been announced for HealthifyMe.
How can I track HealthifyMe secondary market activity?
Caplight tracks bids, offers, and trades in HealthifyMe's shares on secondary markets.